Determination of fraction unbound docetaxel using microequilibrium dialysis

Analytical Biochemistry

Volumn 331, Issue 1, 2004, Pages 192-194

  Acharya, Milin R ^a   Baker, Sharyn D ^b   Verweij, Jaap ^c   Figg, William D ^a   Sparreboom, Alex ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY;

DOCETAXEL; FRACTION UNBOUND;

CHEMISTRY;

DOCETAXEL; EXCIPIENT; PLASMA PROTEIN; POLYSORBATE 80;

ANALYTICAL EQUIPMENT; ARTICLE; BREAST CANCER; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; DRUG DETERMINATION; EQUILIBRIUM DIALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 3042789986     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-2697(04)00297-0     Document Type: Article

References (9)

1. Nabholtz J.M., Vannetzel J.M., Llory J.F., Boufette P. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Clin. Breast Cancer. 4:2003;187-192
2. Simon G.R., Bunn P.A. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 21:2003;87-104
3. Urien S., Barre J., Morin C., Paccaly A., Montay G., Tillement J.P. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest. New Drugs. 14:1996;147-151
4. Bruno R., Hille D., Riva A., Vivier N., ten Bokkel Huinnink W.W., van Oosterom A.T., Kaye S.B., Verweij J., Fossella F.V., Valero V., Rigas J.R., Seidman A.D., Chevallier B., Fumoleau P., Burris H.A., Ravdin P.M., Sheiner L.B. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J. Clin. Oncol. 16:1998;187-196
5. Bruno R., Vivier N., Veyrat-Follet C., Montay G., Rhodes G.R. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest. New Drugs. 19:2001;163-169
6. Loos W.J., Baker S.D., Verweij J., Boonstra J., Sparreboom A. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin. Pharmacol. Ther. 74:2003;364-371
7. Baker S.D., Zhao M., Lee C.K.K., Verweij J., Zabelina Y., Brahmer J.R., Wolff A.C., Sparreboom A., Carducci M.A. Comparative pharmacokinetics of weekly and every-3-week docetaxel. Clin. Cancer Res. 10:2004;1976-1983
8. Ten Tije A.J., Loos W.J., Verweij J., Baker S.D., Dinh K., Figg W.D., Sparreboom A. Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin. Pharmacol. Ther. 74:2003;509-510
9. Baker S.D., Zhao M., He P., Carducci M.A., Verweij J., Sparreboom A. Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal. Biochem. 324:2004;276-284